Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children

被引:31
作者
Resino, S
Bellón, JM
Resino, R
Navarro, ML
Ramos, JT
de Jose, MI
Mellado, MJ
Muñoz-Frenández, MA
机构
[1] Hosp Gregorio Maranon, Lab Inmunobiol, Madrid, Spain
[2] Hosp Gregorio Maranon, Serv Inmuno Pediat, Madrid, Spain
[3] Hosp 12 Octubre, Serv Inmunopediat, E-28041 Madrid, Spain
[4] Hosp La Paz, Serv Pediat, Madrid, Spain
[5] Hosp Carlos III Madrid, Serv Pediat Infecciosas, Madrid, Spain
关键词
D O I
10.1086/420738
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We performed a retrospective observational study of 253 children vertically infected with human immunodeficiency virus (1994-2001) to assess the effectiveness of antiretroviral therapies (ARTs) on survival and surrogate markers at the population level. Children were divided into 3 groups according to the ART protocols used during the follow-up period: calendar period (CP) 1 (1994-1996) received combined therapy with 2 nucleoside reverse transcriptase inhibitors (NRTIs); CP2 (1997-1998) received implementation of highly active ART ( HAART) with 3 drugs ( NRTIs, protease inhibitors, and non-NRTIs); and CP3 (1999-2001) received extensive HAART. The children in the CP3 group had statistically significant longer survival periods, lower virus load (VL), highest undetectable VL proportion, and highest CD4(+) T cell counts. HAART is effective at the population level at decreasing VL, increasing CD4(+) T cells, and increasing the survival in a higher percentage of HIV-infected children.
引用
收藏
页码:1605 / 1612
页数:8
相关论文
共 38 条
[1]  
Aboulker JP, 2002, LANCET, V359, P733
[2]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[3]  
[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1
[4]   Morbidity and mortality in European children vertically infected by HIV-1 - The French pediatric HIV infection study group and European collaborative study [J].
Blanche, S ;
Newell, ML ;
Mayaux, MJ ;
Dunn, DT ;
Teglas, JP ;
Rouzioux, C ;
Peckham, CS .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 14 (05) :442-450
[5]  
*CDCP, 1998, MMWR-MORBID MORTAL W, V47, P315
[6]  
Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P285
[7]   Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA [J].
Clumeck, N ;
Goebel, F ;
Rozenbaum, W ;
Gerstoft, J ;
Staszewski, S ;
Montaner, J ;
Johnson, M ;
Gazzard, B ;
Stone, C ;
Athisegaran, R ;
Moore, S .
AIDS, 2001, 15 (12) :1517-1526
[8]   Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus [J].
Cooper, CL ;
Parbhakar, MA ;
Angel, JB .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (09) :1259-1263
[9]   Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection [J].
de Martino, M ;
Tovo, PA ;
Balducci, M ;
Galli, L ;
Gabiano, C ;
Rezza, G ;
Pezzotti, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (02) :190-197
[10]   Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis [J].
Detels, R ;
Tarwater, P ;
Phair, JP ;
Margolick, J ;
Riddler, SA ;
Muñoz, A .
AIDS, 2001, 15 (03) :347-355